AU2003272390A8 - Ampds as modifiers of the p21 pathway and methods of use - Google Patents

Ampds as modifiers of the p21 pathway and methods of use

Info

Publication number
AU2003272390A8
AU2003272390A8 AU2003272390A AU2003272390A AU2003272390A8 AU 2003272390 A8 AU2003272390 A8 AU 2003272390A8 AU 2003272390 A AU2003272390 A AU 2003272390A AU 2003272390 A AU2003272390 A AU 2003272390A AU 2003272390 A8 AU2003272390 A8 AU 2003272390A8
Authority
AU
Australia
Prior art keywords
ampds
modifiers
pathway
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2003272390A
Other versions
AU2003272390A1 (en
Inventor
Siobhan Roche
Lori Friedman
Thomas Kidd
Helen Francis-Lang
Kim Lickteig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2003272390A1 publication Critical patent/AU2003272390A1/en
Publication of AU2003272390A8 publication Critical patent/AU2003272390A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003272390A 2002-09-16 2003-09-15 AMPDs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE Abandoned AU2003272390A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41101002P 2002-09-16 2002-09-16
US60/411,010 2002-09-16
PCT/US2003/028899 WO2004024880A2 (en) 2002-09-16 2003-09-15 AMPDs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE

Publications (2)

Publication Number Publication Date
AU2003272390A1 AU2003272390A1 (en) 2004-04-30
AU2003272390A8 true AU2003272390A8 (en) 2004-04-30

Family

ID=31994236

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2003270662A Abandoned AU2003270662A1 (en) 2002-09-16 2003-09-15 RORs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
AU2003272390A Abandoned AU2003272390A1 (en) 2002-09-16 2003-09-15 AMPDs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
AU2003278812A Abandoned AU2003278812A1 (en) 2002-09-16 2003-09-15 FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
AU2003272400A Abandoned AU2003272400A1 (en) 2002-09-16 2003-09-15 Syts as modifiers of the p21 pathway and methods of use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2003270662A Abandoned AU2003270662A1 (en) 2002-09-16 2003-09-15 RORs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2003278812A Abandoned AU2003278812A1 (en) 2002-09-16 2003-09-15 FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
AU2003272400A Abandoned AU2003272400A1 (en) 2002-09-16 2003-09-15 Syts as modifiers of the p21 pathway and methods of use

Country Status (6)

Country Link
US (2) US20060101530A1 (en)
EP (2) EP1546703A2 (en)
JP (2) JP2006513698A (en)
AU (4) AU2003270662A1 (en)
CA (2) CA2497790A1 (en)
WO (4) WO2004024879A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101808863B1 (en) 2011-12-31 2017-12-14 서울대학교산학협력단 Screening Methods of apoptotic inducer agents using ROR
EP3211081A1 (en) * 2016-02-26 2017-08-30 Secarna Pharmaceuticals GmbH & Co. KG Novel approach for treating inflammatory disorders
DK3420084T3 (en) 2016-02-26 2021-10-25 Secarna Pharmaceuticals Gmbh & Co Kg UNPERMANENT APPROACH TO TREATMENT OF INFLAMMATORY DISORDERS
TW202306993A (en) 2021-05-14 2023-02-16 美商建南德克公司 Agonists of trem2
WO2024020564A1 (en) 2022-07-22 2024-01-25 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0609240B1 (en) 1991-09-17 2002-04-03 The Salk Institute For Biological Studies Receptors of the thyroid/steroid hormone receptor superfamily
AU1210300A (en) 1998-10-23 2000-05-15 Tularik Inc. Human retinoid-like orphan receptor gamma
US20020108138A1 (en) * 2000-06-29 2002-08-08 Catherine Guenther Transgenic mice containing RORgamma gene disruptions
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
MXPA03006617A (en) * 2001-01-24 2004-12-02 Protein Design Labs Inc Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer.

Also Published As

Publication number Publication date
AU2003278812A1 (en) 2004-04-30
US8426147B2 (en) 2013-04-23
WO2004024879A2 (en) 2004-03-25
EP1546703A2 (en) 2005-06-29
US20060101530A1 (en) 2006-05-11
CA2497793A1 (en) 2004-03-25
AU2003272400A8 (en) 2004-04-30
EP1578934A2 (en) 2005-09-28
AU2003272400A1 (en) 2004-04-30
EP1578934A4 (en) 2007-12-12
US20090149413A1 (en) 2009-06-11
AU2003270662A1 (en) 2004-04-30
JP2006513698A (en) 2006-04-27
CA2497790A1 (en) 2004-03-25
AU2003272390A1 (en) 2004-04-30
WO2004024880A2 (en) 2004-03-25
WO2004024879A3 (en) 2004-07-15
WO2004024884A2 (en) 2004-03-25
WO2004024880A3 (en) 2004-10-07
WO2004024882A3 (en) 2006-12-07
WO2004024882A2 (en) 2004-03-25
WO2004024884A3 (en) 2004-07-22
JP2005538722A (en) 2005-12-22

Similar Documents

Publication Publication Date Title
AU2003216482A8 (en) Msras as modifiers of the p53 pathway and methods of use
EP1651956A4 (en) Melks as modifiers of the rac pathway and methods of use
AU2003272400A8 (en) Syts as modifiers of the p21 pathway and methods of use
EP1535067A4 (en) PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
AU2003251826A8 (en) Mp21s as modifiers of the p21 pathway and methods of use
EP1534852A4 (en) CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
AU2003265263A1 (en) ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
AU2003251799A1 (en) Mchks as modifiers of the chk1 pathway and methods of use
AU2003223208A8 (en) Mp21s as modifiers of the p21 pathway and methods of use
AU2003274911A8 (en) Mrbs as modifiers of the rb pathway and methods of use
AU2003303094A8 (en) Mat2as as modifiers of the p53 pathway and methods of use
EP1412477A4 (en) GPCs AS MODIFIERS OF THE IRRTK AND P21 PATHWAYS AND METHODS OF USE
AU2003263993A8 (en) Mp2153s as modifiers of the p21 or p53 pathway and methods of use
AU2003294499A8 (en) Rhebs as modifiers of the rb pathway and methods of use
EP1578945A3 (en) Cct6s as modifiers of the rb pathway and methods of use
EP1540333A4 (en) Maxs as modifiers of the axin pathway and methods of use
AU2003213693A8 (en) Mchks as modifiers of the chk pathway and methods of use
AU2003213665A8 (en) Lgals as modifiers of the chk pathway and methods of use
AU2003299990A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003217851A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003278811A8 (en) Ldlrs as modifiers of the p53 pathway and methods of use
EP1587910A4 (en) Facls as modifiers of the rb pathway and methods of use
EP1687405A4 (en) Ttbks as modifiers of the beta catenin pathway and methods of use
EP1633852A4 (en) Sppls as modifiers of the p53 pathway and methods of use
AU2003213662A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase